Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of CYD Dengue Vaccine in Latin American Children
NCT01374516Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2011
- Primary completion
- Nov 2014
- Modality
- Live Attenuated Vaccines, Recombinant Vaccines
- Countries
- 5
01
Overview
A Phase 3 trial of Cyd dengue virus serotype 1 live (attenuated) antigen in dengue fever, sponsored by Sanofi. Started Jun 2011; status: completed.
02
Drugs
Cyd dengue virus serotype 1 live (attenuated) antigen
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT01374516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01374516.